Heranba Industries Limited · NSE:HERANBA
Heranba Industries — Q4 FY2022 Earnings Presentation
25 slides from Heranba Industries's earnings presentation, May 2022
Slide 1: Investor Presentation Q4FY22
Investor Presentation Q4FY22 || May 2022 BSE: 543266 | NSE: HERANBA | ISIN: INE694N01015 www.heranba.co.in
Slide 2: Safe Harbor
Safe This presentation and the accompanying slides (the “Presentation”), which have been prepared by Heranba Industries Harbor Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any se
Slide 3: Contents
Contents Company Overview 01 SLIDE 04 Management Team 02 SLIDE 11 Quarterly Performance 03 SLIDE 13 Financial Performance 04 SLIDE 17 Strategy for Growth 05 SLIDE 22
Slide 4: Company Overview
Section: 01 Company Overview Heranba at glance Our journey Value chain SLIDE 05 SLIDE 06 SLIDE 07 Intermediaries Technicals Formulations SLIDE 08 SLIDE 09 SLIDE 10
Slide 5: Heranba at a Glance
Heranba at a Glance 60+ 4 65+ 700+ Revenue from Institutional Manufacturing Countries Employees customers** Facilities Presence (as of FY22) (as of FY22) 9400+ 42% ~25% Dealers Revenue from Revenue from 30.4% Exports as % of sales Top 10 customers ROE# across India (as of FY22) (as of FY22) (as of F
Slide 6: Our Journey
Our Journey FORMULATIONS Forward integrated into the manufacturing ISO CERTIFICATE of Formulations developed from Company’s Receipt of ISO 9001:2015 synthetic pyrethroids product portfolio of certification in respect of production EXPORTS CMAC cypermethrin, alphacypermethrin, & dispatch of agro Form
Slide 7: Value Chain
Value Chain Manufacturing Process ▪ The process of manufacturing ▪ HIL manufactures a wide range of products, and each product has its can be classified broadly into own unique manufacturing process three stages Value Chain ▪ The Company specializes in the manufacturing processes that mainly include
Slide 8: Intermediaries
Intermediaries Cypermethric Acid Chloride (CMAC) End-use High CIS CMA High Trans CMA Intermediates manufactured are for Company’s own captive consumption for manufacturing various Technicals and Formulations Metaphenoxy High Trans CMAC Bromobenzenes Benzaldehyde (MPBD)
Slide 9: Management
An ISO 9001:2015 Company (@) HERANBA INDUSTRIES LIMITED Section: 02 Management
Slide 10: Experienced Promoters with Domain Knowledge
Experienced Promoters with Domain Knowledge Promoters having a cumulative experience of more than six decades Mr. Sadashiv K. Shetty Mr. Raghuram K. Shetty Chairman and Executive Director Managing Director ▪ Holds a bachelor’s (physics and chemistry) and master’s (chemistry) ▪ Holds a bachelor’s deg
Slide 11: Quarterly Performance
Section: 03 Quarterly Performance Quarterly Financial Highlights P&L Summary Performace SLIDE 14 SLIDE 16 SLIDE 15
Slide 12: Q4FY22 Financial Highlights
Q4FY22 Financial Highlights ▪ Revenue from Operations at ₹3,501 million in Q4FY22 as compared to ₹2,678 million in Q4FY21 – growth of 30.73% Y-o-Y. ▪ EBITDA (incl. other income) at ₹673 million in Q4FY22 as compared to ₹630 million in Q4FY21 – growth of 6.77% Y-o-Y. ▪ EBITDA (incl. other income) Mar
Slide 13: Quarterly Performance
Quarterly Performance Net Revenue from EBITDA(incl. Other Rev) PAT and PAT Margin Business Mix Operations and EBITDA Margin (₹ IN MILLION & %) (IN %) (₹ IN MILLION) (IN ₹ MILLION & %) 4,500 13% 23.54% 4,000 16.15% 22% 3,500 19.31% 19.23% 13.52% 3,000 12.16% 2,500 3,953.94 32% 3,501.38 2,000 2,678.30
Slide 14: Profit & Loss Summary (Quarterly)
Profit & Loss Summary (Quarterly) Figures in Rs Million, except EPS and Margins PARTICULARS Q4FY21 Q3FY22 Q4FY22 Revenue from Operations 2,678 3,954 3,501 Other Income 53 51 48 Total Revenue 2,732 4,005 3,549 Total Expenses 2,154 3,293 2,967 Profit Before Tax 578 713 583 Total Tax Expense 145 178 15
Slide 15: Financial Performance
Section: 04 Financial Performance Key Ratios Financial Summary SLIDE 18 SLIDE 20
Slide 16: Key Financial Metrics
Key Financial Metrics Net Revenue EBITDA(incl. Other Rev) PAT and Net Debt/(Cash) from Operations and EBITDA Margin PAT Margin and Equity (₹ IN MILLION) (IN ₹ MILLION & %) (₹ IN MILLION & %) (₹ IN MILLION) 13.04% 12.66% 14,503.57 10.26% (675.42) 12,186.47 19.24% 18.74% 7.51% 10,044.44 (345.01) 15.33
Slide 17: Business Mix
Business Mix Diversified customers base across geographies helps to mitigate risks and benefit from expected growth in agrochemical market Revenue from Operations Revenue from Domestic / Exports (IN%) (% OF SALES) Export Revenue Split: Technical and Formulations Export 32% 36% 39% 42% 39% 48% 49% 49
Slide 18: Profit & Loss Summary
Profit & Loss Summary (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 FY22 Revenue from Operations 10,044.44 9,513.74 12,186.47 14,503.73 Other Income 73.94 165.32 70.30 193.50 Total Revenue 10,118.38 9,679.06 12,256.77 14,697.23 Total Expenses 8,897.18 8,390.64 10,173.92 12,144.73 Profit Before Tax 1,221
Slide 19: Balance Sheet (1/2)
Balance Sheet (1/2) (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 FY22 Non-Current Assets Property, plant and equipment 511.39 954.41 1,334.35 1,934.26 Capital work-in-progress 159.70 377.72 96.95 142.29 Financial Assets: (i) Investments 0.24 37.31 100.98 21.27 (ii) Other Financial Assets 71 84.27 241.7
Slide 20: Balance Sheet (2/2)
Balance Sheet (2/2) (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 FY22 Equity and liabilities Equity Equity share capital 390.56 390.56 400.13 400.13 Other equity 1891.2 2817.93 4881.21 6,744.45 Total Equity 2281.76 3208.49 5281.34 7,144.58 Liabilities Non-Current Liabilities Financial Liabilities (i) B
Slide 21: Cashflow Statement
Cashflow Statement (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 FY22 Cash Flow from Operations 877.02 542.11 603.98 981.8 Cash Flow from Investing Activities -373.79 -520.39 -407.13 -816.8 Cash Flow from financing Activities -411.35 -199.43 619.01 -62.8 Net increase/ (decrease) in cash and cash equival
Slide 22: Strategy for growth
Section: 05 Strategy for growth Competetive Strengths Business Strategy SLIDE 25 SLIDE 27
Slide 23: Competitive Strengths
Competitive Strengths Experienced Promoters and Management Team Wide Distribution Wide range of products Network across value chain Integrated Diversified Manufacturing Units Customer Base Exports to more Product Registration than 60 countries enabling global outreach
Slide 24: Business Strategy
Business Strategy Well positioned to exploit opportunities offered by growth in Agrochemicals Entering Highly Strengthening of Enhancing Enhancing Branded Regulated USA and R&D Facility Production Formulation Formulations and Europe markets Capabilities & Technicals in Public Health International Ma
Slide 25: Thank You
Corporate Office Investor Relations Contacts: Heranba Industries Ltd. Kanav Khanna 101/102, Kanchanganga, ✉kkhanna@christensenir.com Factory Lane, Borivali (W), Mumbai – 400 092, India Diwakar Pingle Tel : 91-22-2898 7912/14, ✉dpingle@christensenir.com 91-22-2898 2133/44, 91-22-2898 4439, 91-22-5070